Literature DB >> 32292661

Seroprevalence of Rubella Virus-specific Antibodies in Women and the Diagnostic Efficacy of Enzyme-linked Immunoassay and Rapid Immunochromatographic Tests.

Praveen R Shahapur1, Venkataramana Kandi2.   

Abstract

Introduction Rubella is an infectious disease caused by the Rubella virus. The disease was previously called German measles and is transmitted through respiratory aerosols. Rubella causes both clinical and subclinical infections in children and young adults. Rubella virus has teratogenic capabilities and may cause severe complications in the fetuses of women who acquire Rubella viral infection during their pregnancy. The present study aims to evaluate the seroprevalence of anti-Rubella virus immunoglobulin (Ig) G and IgM antibodies in both pregnant and non-pregnant women and assess the diagnostic efficacy of enzyme-linked immunosorbent assay (ELISA) and rapid immunochromatographic tests. Methods The study included 240 females in the age range of 16-45 years. The study subjects included both pregnant women and non-pregnant women. After informed consent, 5 milliliters of blood was collected from each participant, and serum was separated and tested for the presence of antibodies (IgG and IgM) against the Rubella virus using both the traditional ELISA (Delta Biologicals, Pvt. Ltd., China) and a rapid ELISA-immunochromatographic test (ICT) (Span Biotech. Ltd., China). The data collected were systematically entered into Microsoft Excel sheets (Microsoft Corporation, Redmond, Washington) and were analyzed using SPSS Statistics for Windows, Version 17.0, 2008 (SPSS Inc., Chicago, Illinois). Results The study revealed an overall seroprevalence of 31.66% for Rubella-specific IgG and IgM antibodies. Out of the 125 pregnant women included in the study, 49 (39.20%) were seropositive for Rubella IgG antibodies, and among the 115 non-pregnant women tested, 24 (20.86%) were positive for Rubella IgG antibodies. Four (5.26%) of the 76 seropositive women revealed IgM antibodies. The sensitivities of both the ELISA (40.61%) and rapid immunochromatographic (39.20%) tests were observed to be low and the specificities of both methods were similar (79.13%). Conclusion The seroprevalence of Rubella-specific IgG antibodies was observed to be low as compared to the other regions of India. The low seroprevalence may predispose pregnant women to Rubella viral infection and may lead to increased incidences of congenital Rubella syndrome (CRS). Both the ELISA and immunochromatographic tests showed low sensitivity and similar specificities.
Copyright © 2020, Shahapur et al.

Entities:  

Keywords:  children; diagnostic efficacy; enzyme linked immunosorbent assay (elisa); pregnant women; rapid immunochromatographic tests; rubella virus; seroprevalence; young adults

Year:  2020        PMID: 32292661      PMCID: PMC7152573          DOI: 10.7759/cureus.7246

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  22 in total

1.  Seroprevalence of rubella and immunogenicity following rubella vaccination in adolescent girls in India.

Authors:  Hitt J Sharma; Vasant S Padbidri; Subhash V Kapre; Suresh S Jadhav; Rajeev M Dhere; Sameer S Parekh; Ashok D Dudhane; Sunil D Shewale; Gajanan S Namjoshi
Journal:  J Infect Dev Ctries       Date:  2011-12-13       Impact factor: 0.968

2.  Congenital cataract following German measles in the mother. 1941.

Authors:  N M Gregg
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

3.  Global seroprevalence of rubella among pregnant and childbearing age women: a meta-analysis.

Authors:  E Pandolfi; F Gesualdo; C Rizzo; A Bella; E Agricola; P Mastroiacovo; A E Tozzi
Journal:  Eur J Public Health       Date:  2017-06-01       Impact factor: 3.367

4.  Rubella seroprevalence and demographic feature analysis in pregnant women from Southern Pakistan.

Authors:  Aamir Khan; Hazir Rahman; Rabia Noushin; Syed Ishtiaq Anjum; Faryal Saad; Kalim Ullah
Journal:  J Pak Med Assoc       Date:  2019-08       Impact factor: 0.781

5.  Characterization of rubella seronegative females in the zambian blood donor community.

Authors:  Mazyanga L Mazaba; Mwaka Monze; Olusegun A Babaniyi; Seter Siziya; Charles Michelo
Journal:  Front Public Health       Date:  2015-04-24

6.  Seroprevalence of rubella-specific IgM and IgG antibodies among pregnant women seen in a tertiary hospital in Nigeria.

Authors:  Okikiola M Olajide; Maryam Aminu; Abdullahi J Randawa; Daniel S Adejo
Journal:  Int J Womens Health       Date:  2015-01-06

7.  Rubella sero-prevalence among children in Kilimanjaro region: a community based study prior to the introduction of rubella vaccine in Tanzania.

Authors:  Nikolas A S Chotta; Melina Mgongo; Jacqueline G Uriyo; Sia E Msuya; Babill Stray-Pedersen; Arne Stray-Pedersen
Journal:  Ital J Pediatr       Date:  2017-07-21       Impact factor: 2.638

8.  Seroprevalance of Rubella in an Urban Infertility Clinic - Observations and Challenges Ahead.

Authors:  Aby Kottal Koshy; Jijo George Varghese; Jeethu Issac
Journal:  J Hum Reprod Sci       Date:  2018 Oct-Dec

9.  Rubella seroprevalence among pregnant women in Beijing, China.

Authors:  Qinghong Meng; Jie Luo; Lijun Li; Wei Shi; Jinqian Yu; Yingjie Shen; Li Li; Yajuan Wang; Kaihu Yao
Journal:  BMC Infect Dis       Date:  2018-03-15       Impact factor: 3.090

10.  Seroprevalence of rubella virus antibodies among pregnant women in the Center and South-West regions of Cameroon.

Authors:  Nadesh Ashukem Taku; Valantine Ngum Ndze; Emily Abernathy; LiJuan Hao; Diane Waku-Kouomou; Joseph P Icenogle; Samuel Wanji; Jane-Francis K T Akoachere
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

View more
  1 in total

1.  The Burden of Likely Rubella Infection among Healthy Pregnant Women in Abakaliki, Ebonyi State, Nigeria.

Authors:  Uchechukwu Onyeukwu Ekuma; Ogbonnaya Ogbu; Angus Nnamdi Oli; Martin-Luther Oseni Okolo; Peter Anyigor Edeh; Hussein O M Al-Dahmoshi; Sousan Akrami; Morteza Saki
Journal:  Interdiscip Perspect Infect Dis       Date:  2022-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.